Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Up – Here’s What Happened
by Amy Steele · The Cerbat GemBavarian Nordic (OTCMKTS:BVNRY – Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $9.69, but opened at $10.19. Bavarian Nordic shares last traded at $10.07, with a volume of 10,418 shares.
Bavarian Nordic Price Performance
The company has a market capitalization of $2.39 billion, a P/E ratio of 13.21 and a beta of 1.21. The company has a 50 day moving average of $9.85 and a 200-day moving average of $10.04.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $165.70 million for the quarter. Bavarian Nordic had a return on equity of 9.37% and a net margin of 19.74%.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.
The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.